Sesen Bio Inc
F:PCBK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sesen Bio Inc
F:PCBK
|
US |
|
C
|
Crixus Bh3 Acquisition Co
NASDAQ:BHAC
|
US |
|
P
|
Phillips Edison & Co Inc
NASDAQ:PECO
|
US |
|
P
|
Patels Airtemp (India) Ltd
BSE:517417
|
IN |
|
Energy Transition Minerals Ltd
ASX:ETM
|
AU |
|
F
|
Financiera Independencia SAB de CV SOFOM ENR
BMV:FINDEP
|
MX |
|
CrowdStrike Holdings Inc
NASDAQ:CRWD
|
US |
|
Central Puerto SA
NYSE:CEPU
|
AR |
|
Shiseido Co Ltd
TSE:4911
|
JP |
|
M
|
Meta Health Ltd
SGX:5DX
|
SG |
|
N
|
Netmed Inc
OTC:NTME
|
US |
Sesen Bio Inc
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
